High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction
- 13 June 2000
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 101 (23), 2690-2695
- https://doi.org/10.1161/01.cir.101.23.2690
Abstract
Background —We evaluated platelet activation and aggregation in patients with acute myocardial infarction (AMI) treated with thrombolytic therapy alone or with reduced-dose thrombolysis and concomitant abciximab. Methods and Results —The study was performed in 20 control subjects and 51 patients with AMI before and after reperfusion with either alteplase or reteplase or reduced doses of these agents with concomitant abciximab. Platelet activation was assayed by platelet surface expression of P-selectin. Turbidometric platelet aggregation in response to ADP was measured in patients before thrombolytic therapy and 90 minutes and 24 hours after the beginning of thrombolytic therapy. P-selectin expression was greater at baseline in patients than normal control subjects (30.4% versus 9.8%, P P =0.37). However, at 24 hours, basal P-selectin expression declined in patients ( P =0.0025 versus baseline), whereas ADP-stimulated P-selectin expression was lower in patients than in control subjects (48% versus 69%, P =0.0004). When combined with reduced doses of either alteplase or reteplase, abciximab achieved 91% and 83% inhibition of 5 and 20 μmol/L ADP–induced platelet aggregation, which decreased to 46% and 40%, respectively, at 24 hours. No appreciable difference in the platelet inhibition profile of abciximab was observed between the 2 thrombolytics. Conclusions —Platelet activation and aggregation are heightened in the setting of thrombolysis for AMI. Despite this enhanced level of platelet activation, abciximab, combined with a reduced-dose thrombolytic, inhibited platelet aggregation similarly to the level reported in elective settings.Keywords
This publication has 22 references indexed in Scilit:
- Effects of Reteplase and Alteplase on Platelet Aggregation and Major Receptor Expression During the First 24 Hours of Acute Myocardial Infarction TreatmentJournal of the American College of Cardiology, 1998
- Time course of platelet alpha granule release in acute myocardial infarction treated with streptokinase.Heart, 1996
- Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptorsJournal of the American College of Cardiology, 1995
- Platelet receptor desensitization induced by elevated prostacyclin levels causes platelet-endothelial cell adhesionJournal of the American College of Cardiology, 1995
- Flow cytometry reveals activated GP IIb???IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarctionBlood Coagulation & Fibrinolysis, 1995
- Coronary Thrombolysis -- A Perspective for the Practicing PhysicianNew England Journal of Medicine, 1993
- Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy: Results of the thrombolysis and angioplasty in mycardial infaraction (TAMI) 8 pilot studyJournal of the American College of Cardiology, 1993
- Flow Cytometric Measurement of Platelet Function and Reticulated Platelets.Annals of the New York Academy of Sciences, 1993
- Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarctionHeart, 1992
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985